Pionyr Immunotherapeutics raises $8mm through Series A-1 round
Executive Summary
Oncology start-up Pionyr Immunotherapeutics Inc. raised $8mm through its Series A-1 round. OrbiMed and SV Life Sciences co-led and were joined by Osage University Partners, Mission Bay Ventures, private angel backers, and individual investors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice